Impact of cardiac complications on transplant outcomes
| Univariate analysis . | OS, HR (95% CI) . | P value . | NRM, HR (95% CI) . | P value . |
|---|---|---|---|---|
| CEs | ||||
| All events (time dependent) | 1.98 (1.42-2.78) | <.001 | 3.73 (2.44-5.70) | <.001 |
| CEs | ||||
| ECE (time dependent) | 1.72 (1.16-2.56) | <.001 | 5.72 (3.43-9.54) | <.001 |
| LCE (time dependent) | 2.51 (1.46-4.31) | <.001 | 5.53 (2.60-11.79) | <.001 |
| GVHD prophylaxis | ||||
| PTCY-based (vs others) | 0.87 (0.71-1.06) | .188 | 1.14 (0.86-1.53) | .35 |
| Univariate analysis . | OS, HR (95% CI) . | P value . | NRM, HR (95% CI) . | P value . |
|---|---|---|---|---|
| CEs | ||||
| All events (time dependent) | 1.98 (1.42-2.78) | <.001 | 3.73 (2.44-5.70) | <.001 |
| CEs | ||||
| ECE (time dependent) | 1.72 (1.16-2.56) | <.001 | 5.72 (3.43-9.54) | <.001 |
| LCE (time dependent) | 2.51 (1.46-4.31) | <.001 | 5.53 (2.60-11.79) | <.001 |
| GVHD prophylaxis | ||||
| PTCY-based (vs others) | 0.87 (0.71-1.06) | .188 | 1.14 (0.86-1.53) | .35 |
| MVA . | OS HR (95% CI) . | P value . | NRM HR (95% CI) . | P value . |
|---|---|---|---|---|
| CEs | ||||
| All events (time dependent) | 1.65 (1.16-2.34) | .005 | 2.88 (1.74-4.76) | <.001 |
| GVHD prophylaxis | ||||
| PTCY-based (vs others) | 0.71 (0.53-0.96) | .026 | 0.81 (0.50-1.29) | .381 |
| Patient age, y | ||||
| >59 (vs younger) | 1.16 (0.91-1.49) | .223 | 1.37 (0.91-2.02) | .133 |
| HTN | ||||
| Yes (vs no) | 1.06 (0.81-1.39) | .653 | 1.29 (0.84-1.96) | .231 |
| DLP | ||||
| Yes (vs no) | 1.38 (1.03-1.85) | .003 | 1.40 (0.89-2.21) | .139 |
| HCT-CI | ||||
| >3 (vs 0-3) | 1.26 (0.96-1.65) | .086 | 1.32 (0.87-2.02) | .184 |
| Disease status before allo-HCT | ||||
| Refractory AML/active disease (vs complete remission) | 2.50 (1.88-3.32) | <.001 | N/A | |
| Intensity | ||||
| RIC (vs MAC) | 1.13 (0.89-1.43) | .283 | 1.05 (0.73-1.51) | .772 |
| Donor | ||||
| Haploidentical (vs others) | 1.28 (0.93-1.77) | .120 | 1.33 (0.79-2.25) | .267 |
| Grade 3-4 aGVHD | ||||
| Time-dependent variable | 2.21 (1.67-2.92) | <.001 | 8.38 (5.98-11.75) | <.001 |
| MVA . | OS HR (95% CI) . | P value . | NRM HR (95% CI) . | P value . |
|---|---|---|---|---|
| CEs | ||||
| All events (time dependent) | 1.65 (1.16-2.34) | .005 | 2.88 (1.74-4.76) | <.001 |
| GVHD prophylaxis | ||||
| PTCY-based (vs others) | 0.71 (0.53-0.96) | .026 | 0.81 (0.50-1.29) | .381 |
| Patient age, y | ||||
| >59 (vs younger) | 1.16 (0.91-1.49) | .223 | 1.37 (0.91-2.02) | .133 |
| HTN | ||||
| Yes (vs no) | 1.06 (0.81-1.39) | .653 | 1.29 (0.84-1.96) | .231 |
| DLP | ||||
| Yes (vs no) | 1.38 (1.03-1.85) | .003 | 1.40 (0.89-2.21) | .139 |
| HCT-CI | ||||
| >3 (vs 0-3) | 1.26 (0.96-1.65) | .086 | 1.32 (0.87-2.02) | .184 |
| Disease status before allo-HCT | ||||
| Refractory AML/active disease (vs complete remission) | 2.50 (1.88-3.32) | <.001 | N/A | |
| Intensity | ||||
| RIC (vs MAC) | 1.13 (0.89-1.43) | .283 | 1.05 (0.73-1.51) | .772 |
| Donor | ||||
| Haploidentical (vs others) | 1.28 (0.93-1.77) | .120 | 1.33 (0.79-2.25) | .267 |
| Grade 3-4 aGVHD | ||||
| Time-dependent variable | 2.21 (1.67-2.92) | <.001 | 8.38 (5.98-11.75) | <.001 |
The impact of the 95 CEs in outcomes has been investigated in the entire cohort of patients included in the study. CE variable has been treated as a time-dependent variable. CEs occurring after disease relapse have not been accounted. Variables included in the multivariate model were selected based on results from supplemental Section 3 and if considered clinically relevant for the transplant success. The variable HCT-CI has been included instead of the variables prior cardiac toxicity, obesity, or diabetes mellitus.
HCT-CI, HCT–comorbidity index; RIC, reduced intensity conditioning.